Frazier Lifesciences (NASDAQ:FLAC) announced this morning that its shareholders have approved its business combination with biotech firm NewAmsterdam Pharma Holding during a special meeting today.
The SPAC disclosed that holders of approximately 32% of FLAC Class A ordinary shares exercised their right to redeem their shares for cash, significantly lower than the average redemption rate for completed deals this year at 83.99%.
Additionally, more than 90% of the votes cast at today’s meeting were cast in favor of the business combination. FLAC shareholders also voted to approve all other proposals.
FLAC now expects to close the deal on November 22, subject to the satisfaction or waiver of customary closing conditions. Upon closing, the ordinary shares and redeemable warrants of the combined company, NewAmsterdam Pharma Company, will be listed on The Nasdaq under the ticker symbols “NAMS” and “NAMSW” respectively, and are anticipated to begin trading on November 23.
The parties initially announced their $326 million combination on July 25, 2022. Netherlands-based NewAmsterdam is developing a range of drugs aimed at reducing patient cholesterol levels suffering from liver, heart and brain disorders.
ADVISORS
- Credit Suisse Securities (USA) LLC is acting as lead PIPE placement agent, financial advisor, and capital markets advisor to FLAC.
- Jefferies LLC is also acting as PIPE placement agents to FLAC and is acting as financial advisor and capital markets advisor to FLAC.
- SVB Securities LLC is also acting as PIPE placement agents to FLAC and is acting as financial advisor and capital markets advisor to the Company.
- William Blair & Company, L.L.C. is also acting as PIPE placement agents to FLAC and is acting as financial advisor and capital markets advisor to FLAC.
- Moelis & Co. is also acting as financial advisor to the Company.
- Covington & Burling LLP is acting as legal counsel to the Company.
- Goodwin Procter LLP is acting as legal counsel to FLAC.
- Kirkland & Ellis LLP is acting as legal counsel to the PIPE placement agents.
Terms Tracker for the Week Ending July 3, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. We’re heading into the July 4th holiday, so we’ll keep this week’s column short and to the point. But before you head to the beach,...
Crown PropTech (OTC:CPTKW) has entered into a definitive agreement to combine with rare earth mining firm Mkango Resources (TSX-V:MKA) at a pre-money equity value of $400 million. London-based Mkango is working to commercialize a chain of rare earth mining and refining facilities in Africa and Europe. The combined company is expected to trade on the...
At the SPAC of Dawn One of the biggest sources of uncertainty in the SPAC market in recent years has been regulatory changes, but new shifts could be in its favor. SEC Chairman Paul Atkins told CNBC yesterday that the commission would review the rules for SPACs after “rather controversial” changes to the rules passed...
McKinley Acquisition Corporation (NASDAQ:MKLYU) has filed for a $150 million SPAC to hunt for an innovative target company with an experienced financial team that has dabbled in SPACs before. The new SPAC is offering investors one right to a 1/10 share in each unit with no overfunding of the trust, but it could provide a...
At the SPAC of Dawn The rain of SPACs has continued with four expected to make their debuts during today’s trading sessions after pricing their IPOs overnight. The largest of these, EQV Ventures II (NASDAQ:EVACU), even managed an upsize, making it the largest SPAC IPO since Ares II (NYSE:AACT) pulled together $450 million in 2023....